AU3397184A - Enteric film-coating compositions - Google Patents

Enteric film-coating compositions

Info

Publication number
AU3397184A
AU3397184A AU33971/84A AU3397184A AU3397184A AU 3397184 A AU3397184 A AU 3397184A AU 33971/84 A AU33971/84 A AU 33971/84A AU 3397184 A AU3397184 A AU 3397184A AU 3397184 A AU3397184 A AU 3397184A
Authority
AU
Australia
Prior art keywords
coating compositions
enteric film
enteric
film
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU33971/84A
Other languages
English (en)
Inventor
Stuart C Porter
Edward J Woznicki
Andrea Louis F D
Susan M Grillo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Colorcon Inc
Original Assignee
Colorcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Colorcon Inc filed Critical Colorcon Inc
Publication of AU3397184A publication Critical patent/AU3397184A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Paints Or Removers (AREA)
AU33971/84A 1983-09-19 1984-09-07 Enteric film-coating compositions Abandoned AU3397184A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/533,541 US4556552A (en) 1983-09-19 1983-09-19 Enteric film-coating compositions
US533541 1983-09-19

Publications (1)

Publication Number Publication Date
AU3397184A true AU3397184A (en) 1985-04-11

Family

ID=24126414

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33971/84A Abandoned AU3397184A (en) 1983-09-19 1984-09-07 Enteric film-coating compositions

Country Status (8)

Country Link
US (1) US4556552A (enExample)
EP (1) EP0156852A1 (enExample)
JP (1) JPS60502207A (enExample)
KR (1) KR850700009A (enExample)
AU (1) AU3397184A (enExample)
IT (1) IT8448873A0 (enExample)
PH (1) PH21092A (enExample)
WO (1) WO1985001207A1 (enExample)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971791A (en) * 1985-08-26 1990-11-20 The Procter & Gamble Company Taste masking compositions
US5843445A (en) * 1987-06-24 1998-12-01 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US4857337A (en) * 1988-05-24 1989-08-15 American Home Products Corp. (Del) Enteric coated aspirin tablets
DE69127470T2 (de) 1990-03-02 1998-02-19 Autoimmune Inc Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
FR2660317B1 (fr) * 1990-03-27 1994-01-14 Seppic Produit filmogene destine a l'enrobage des formes solides; son procede de fabrication et produits revetus de ce produit.
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5427614A (en) * 1992-02-14 1995-06-27 Warner-Lambert Company Starch based formulations
US6224911B1 (en) * 1993-03-16 2001-05-01 Syntex (U.S.A.) Llc Process for the preparation of enteric coated pharmaceutical dosage forms
US5436011A (en) * 1993-04-16 1995-07-25 Bristol-Myers Squibb Company Solid pharmaceutical dosage form and a method for reducing abrasion
US6113893A (en) * 1993-07-28 2000-09-05 Pfizer Inc. Psoriasis treatment
US5800831A (en) * 1993-07-28 1998-09-01 Pfizer Inc. Psoriasis treatment with polymer film
CA2164344C (en) * 1993-08-30 2004-06-29 Stanley Lech Tablet coating based on a melt-spun mixture of a saccharide and a polymer
DE723436T1 (de) * 1994-07-08 1997-09-11 Astra Ab Aus mehreren einzeleinheiten zusammengesetzte dosierungsform in tablettenform (i)
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
US5591721A (en) * 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US6645943B1 (en) 1994-10-25 2003-11-11 Hybridon, Inc. Method of down-regulating gene expression
US6608035B1 (en) * 1994-10-25 2003-08-19 Hybridon, Inc. Method of down-regulating gene expression
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US5683718A (en) * 1995-04-04 1997-11-04 Time-Cap Labs, Inc. Enteric coated tablet with raised identification character and method of manufacture
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
US7074768B2 (en) 1995-08-17 2006-07-11 Idera Pharmaceuticals, Inc. Modified protein kinase A-specific oligonucleotides and methods of their use
US6624293B1 (en) 1995-08-17 2003-09-23 Hybridon, Inc. Modified protein kinase A-specific oligonucleotides and methods of their use
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US5807580A (en) * 1996-10-30 1998-09-15 Mcneil-Ppc, Inc. Film coated tablet compositions having enhanced disintegration characteristics
US5877309A (en) 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US6809193B2 (en) 1997-08-13 2004-10-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US20070149472A1 (en) * 1997-08-13 2007-06-28 Mckay Robert Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
CA2300352A1 (en) * 1997-08-19 1999-02-25 Hybridon, Inc. Novel hiv-specific synthetic oligonucleotides and methods of their use
ATE241341T1 (de) 1997-09-10 2003-06-15 Takeda Chemical Industries Ltd Stabilisierte pharmazeutische zusammensetzung
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6300320B1 (en) 1999-01-05 2001-10-09 Isis Pharmaceuticals, Inc. Modulation of c-jun using inhibitors of protein kinase C
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6878749B2 (en) 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6812205B2 (en) 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
ES2292594T3 (es) 2000-05-24 2008-03-16 The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services E-selectina para tratar o prevenir accidentes cerebrovasculares.
JP2004517066A (ja) 2000-11-20 2004-06-10 ダウ グローバル テクノロジーズ インコーポレイティド 水吸収性ポリマーの生体内での使用
TR200300731T2 (tr) 2000-11-28 2004-08-23 Fmc Corporation Yenebilir PGA kaplama bileşimi
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
CA2449175A1 (en) * 2001-06-05 2002-12-12 University Of Chicago Use of methylnaltrexone to treat immune suppression
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US20040028729A1 (en) * 2002-04-29 2004-02-12 Shojaei Amir H. Pharmaceutical formulations with improved bioavailability
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
EP1524981B1 (en) * 2002-07-29 2009-03-11 Glaxo Group Limited Sustained release formulations comprising lamotrigine
CA2521420A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
US20040202755A1 (en) * 2003-04-08 2004-10-14 Myers Gale D. Speckled confection pieces
CA2521369A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
EP1615646B2 (en) 2003-04-08 2022-07-27 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
CA2524495A1 (en) 2003-06-03 2005-01-13 Eli Lilly And Company Modulation of survivin expression
AU2004289222B2 (en) 2003-11-04 2010-01-21 Supernus Pharmaceuticals Inc. Compositions of quaternary ammonium containing bioavailability enhancers
DE602004030931D1 (enExample) * 2003-11-04 2011-02-17 Supernus Pharmaceuticals Inc
AU2005209948B2 (en) 2004-02-06 2009-09-10 Pharmatel (R&D) Pty Limited Use of aminosalicylates in diarrhoea-predominent Irritable Bowel Syndrome
AU2005327506B2 (en) 2004-10-20 2010-07-08 Antisense Therapeutics Ltd Antisense modulation of integrin alpha4 expression
EP1835933A4 (en) 2005-01-04 2015-01-07 Yeda Res & Dev HSP60, HSP60-PEPTIDES AND T-CELL VACCINES FOR IMMUNOMODULATION
US20060205753A1 (en) * 2005-01-20 2006-09-14 Israel Robert J Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
CN104248763A (zh) 2005-03-07 2014-12-31 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US20090068207A1 (en) * 2005-04-15 2009-03-12 Vascular Biogenics Ltd. Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
US20070098790A1 (en) * 2005-10-31 2007-05-03 David Jiang Nutritional supplement for the enhancement of the health of the liver
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
US7731604B2 (en) * 2006-10-31 2010-06-08 Taylor Made Golf Company, Inc. Golf club iron head
KR101483418B1 (ko) * 2007-01-05 2015-01-16 시바 홀딩 인크 퓸드 실리카를 갖는 동시-밀링 유기 안료
JP5469593B2 (ja) 2007-03-29 2014-04-16 ワイス・エルエルシー 末梢性オピオイド受容体アンタゴニストおよびその使用
CA2682129A1 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms and uses thereof
CA2682125C (en) 2007-03-29 2015-06-16 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
JP5277243B2 (ja) 2007-05-11 2013-08-28 トーマス・ジェファーソン・ユニバーシティ 神経変性疾患および障害を治療および阻止する方法
ES2548878T3 (es) * 2007-05-11 2015-10-21 The Trustees Of The University Of Pennsylvania Métodos de tratamiento de úlceras de la piel
RU2010123692A (ru) * 2007-11-13 2011-12-20 Геркулес Инкорпорейтед (Us) Диспергируемая в воде композиция энтеросолюбильного покрытия для нутрицевтических и фармацевтических лекарственных форм
EP3446696A1 (de) * 2007-12-21 2019-02-27 Dr. Willmar Schwabe GmbH & Co. KG Verwendung eines extraktes aus blättern von ginkgo biloba
JP5358587B2 (ja) 2008-02-06 2013-12-04 プロジェニックス・ファーマシューティカルス・インコーポレイテッド （ｒ），（ｒ）−２，２’−ビス−メチルナルトレキソンの製造及び用途
JP5647098B2 (ja) 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
US20110250278A1 (en) 2008-07-01 2011-10-13 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
US20100034959A1 (en) * 2008-08-07 2010-02-11 Vector Corporation High solids, high molecular weight polymer coating
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
EP2651403B1 (en) 2010-12-17 2020-12-02 Glaxo Group Limited Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
WO2013045352A1 (de) 2011-09-30 2013-04-04 Basf Se Verfahren zur herstellung von festen pigmenthaltigen filmüberzugsmitteln in form von granulaten auf basis von magensaftresistenten filmbildnern für pharmazeutische dosierungsformen
US9173884B2 (en) 2011-11-30 2015-11-03 Trustees Of Boston College Inhibitors of phosphodiesterase 11 (PDE11)
RU2014126070A (ru) 2011-12-01 2016-01-27 Глэксо Груп Лимитед Способы лечения и предотвращения глазных заболеваний
US8277842B1 (en) * 2012-01-20 2012-10-02 Dart Neuroscience (Cayman) Ltd. Enteric-coated HT-2157 compositions and methods of their use
BR112015024764B1 (pt) 2013-03-27 2022-06-28 Isarna Therapeutics Gmbh Oligonucleotídeos de tgf-beta modificados, seu uso e composições farmacêuticas que os compreendem
WO2016061531A1 (en) 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
DK3420084T3 (da) 2016-02-26 2021-10-25 Secarna Pharmaceuticals Gmbh & Co Kg Hidtil ukendt tilgang til behandling af inflammatoriske forstyrrelser
EP3211081A1 (en) 2016-02-26 2017-08-30 Secarna Pharmaceuticals GmbH & Co. KG Novel approach for treating inflammatory disorders
US10883108B2 (en) 2016-03-31 2021-01-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
AU2017339561B2 (en) 2016-10-07 2024-02-01 Secarna Pharmaceuticals Gmbh & Co. Kg Novel approach for treating cancer
WO2018093797A1 (en) 2016-11-15 2018-05-24 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
WO2019070917A1 (en) 2017-10-03 2019-04-11 The Schepens Eye Research Institute, Inc. COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME
US11739326B2 (en) 2017-11-14 2023-08-29 Massachusetts Eye And Ear Infirmary RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
KR20220005045A (ko) 2019-05-03 2022-01-12 세카나 파머씨티컬스 지엠비에이치 엔 씨오. 케이지 종양 치료에 사용하기 위한 pd-l1 안티센스 올리고뉴클레오타이드

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2455790A (en) * 1945-06-09 1948-12-07 Eastman Kodak Co Enteric coatings
CH283585A (de) * 1950-03-15 1952-06-15 Hoffmann La Roche Zur Herstellung von Tablettenüberzügen geeignetes Gemisch.
US2897122A (en) * 1956-10-04 1959-07-28 Frosst & Co Charles E Enteric coated product
US2993837A (en) * 1959-07-13 1961-07-25 Frosst & Co Charles E Enteric coated tablets
US3325365A (en) * 1963-04-02 1967-06-13 Ciba Geigy Corp Enteric composition for tablet compression coating
US3449489A (en) * 1965-10-21 1969-06-10 William E Gaunt Pharmaceutical compositions and their preparation
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
DE2612889B1 (de) * 1976-03-26 1977-09-01 Basf Ag UEberzugsmittel fuer Arzneiformlinge
DE2966893D1 (en) * 1978-10-02 1984-05-17 Purdue Research Foundation Foods and pharmaceutical coating composition, method of preparation and products so coated
BE886416A (fr) * 1979-11-29 1981-03-16 Colorcon Composition de revetement comestible seche formant une pelicule, son procede de preparation et produits revetus de ladite composition
US4543370A (en) * 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form

Also Published As

Publication number Publication date
PH21092A (en) 1987-07-16
JPH0534333B2 (enExample) 1993-05-21
IT8448873A0 (it) 1984-09-18
KR850700009A (ko) 1985-10-21
US4556552A (en) 1985-12-03
WO1985001207A1 (en) 1985-03-28
JPS60502207A (ja) 1985-12-19
EP0156852A1 (en) 1985-10-09

Similar Documents

Publication Publication Date Title
AU3397184A (en) Enteric film-coating compositions
AU555915B2 (en) Lipip compositions
AU573240B2 (en) Polyorganosiloxane compositions
GB2136807B (en) Pharmaceutical compositions
AU546367B2 (en) Perokide bleach composition
AU3503984A (en) Pharmaceutical compositions
GB8313217D0 (en) Pharmaceutical compositions
AU566596B2 (en) Bitumenous compositions
GB8325494D0 (en) Pharmaceutical compositions
GB8308126D0 (en) Pharmaceutical compositions
GB8325496D0 (en) Pharmaceutical compositions
AU544594B2 (en) Polyorgansiloxane composition
CY1678A (en) Pharmaceutical compositions
GB2136806B (en) Pharmaceutical compositions
AU550915B2 (en) Epoxy-polymide-rubber composition
GB8317595D0 (en) Pharmaceutical compositions
AU2357784A (en) Aluminium-filled acrylic compositions
CY1503A (en) Pharmaceutical compositions
AU573248B2 (en) Bitumenous compositions
GB8323553D0 (en) Pharmaceutical compositions
AU550877B2 (en) Polyamide-rubber composition
EP0136006A3 (en) Pharmaceutical compositions
AU563927B2 (en) Compositions
GB8305697D0 (en) Pharmaceutical compositions
GB8300767D0 (en) Pharmaceutical compositions